EHA 2018 | Common misconceptions around MRD for MM prognosis

Bruno Paiva

Measurable residual disease (MRD) is used as a prognostic indictor in a variety of hematological maliganancies, including multiple myeloma (MM). We asked Bruno Paiva, PhD, of the University of Navarra, Navarra, Spain, about common misconceptions amongst clinicians when it comes to using MRD as a prognostic marker for MM at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Dr Paiva discusses why patients are often misclassified as MRD-negative, as well as why MRD status should be treated as a simple biomarker that is complemented by other information.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter